Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial

Lancet Oncology

Volumn 8, Issue 4, 2007, Pages 304-310

  Divgi, Chaitanya R ^a   Pandit Taskar, Neeta ^a   Jungbluth, Achim A ^b   Reuter, Victor E ^a   Gönen, Mithat ^a   Ruan, Shutian ^a   Pierre, Christine ^a   Nagel, Andrew ^a   Pryma, Daniel A ^a   Humm, John ^a   Larson, Steven M ^a   Old, Lloyd J ^b   Russo, Paul ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY G250 I 124; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLEAR CELL CARCINOMA; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE COURSE; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; LAPAROTOMY; MALE; NEPHRECTOMY; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHENOTYPE; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; CARCINOMA, RENAL CELL; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; IODINE RADIOISOTOPES; KIDNEY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; PREOPERATIVE CARE; SENSITIVITY AND SPECIFICITY;

EID: 33947504376     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(07)70044-X     Document Type: Article

References (29)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
2. Vasudevan A., Davies R., Shannon B., and Cohen R. Incidental renal tumours: the frequency of benign lesions and the role of preoperative core biopsy. BJU Int 97 (2006) 946-949
3. Linehan W., Walther M., and Zbar B. The genetic basis of cancer of the kidney. J Urol 170 (2003) 2163-2172
4. Kattan M., Reuter V., Motzer R., et al. A postoperative prognostic nomogram for renal cell. J Urol 166 (2001) 63-67
5. Sorbellini M., Kattan M., Snyder M., et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 173 (2005) 48-51
6. Motzer R., Bacik J., Mariani T., et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear cell histology. J Clin Oncol 20 (2002) 2376-2381
7. Lee C., Katz J., Shi W., et al. Surgical management of renal tumors of 4 cm or less in a contemporary cohort. J Urol 163 (2000) 730-736
8. Dash A., Vickers A., Bach A., et al. Comparison of outcomes in elective partial versus radical nephrectomy for clear cell renal cell carcinoma 4-7cm in size. BJU Int 97 (2006) 939-945
9. Oosterwijk E., Divgi C., Brouwers A., et al. Monoclonal antibody-based therapy for renal cell carcinoma. Urol Clin North Am 30 (2003) 623-631
10. Uemura H., Nakagawa Y., Yoshida K., et al. MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br J Cancer 81 (1999) 741-746
11. Bui M., Seligson D., Han K., et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 9 (2003) 802-811
12. Bui M., Visapaa H., Seligson D., et al. Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol 171 (2004) 2461-2466
13. Steffens M., Boerman O., Oosterwijk-Wakka J., et al. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol 15 (1997) 1529-1537
14. Bleumer I., Oosterwijk E., Oosterwijk-Wakka J., et al. A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma. J Urol 175 (2006) 57-62
15. Brouwers A., Buijs W., Mulders P., et al. Radioimmunotherapy with [131I]cG250 in patients with metastasized renal cell cancer: dosimetric analysis and immunologic response. Clin Cancer Res 11 (2005) 7178s-7186s
16. Divgi C., O'Donoghue J., Welt S., et al. Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer. J Nucl Med 45 (2004) 1412-1421
17. Bleumer I., Knuth A., Oosterwijk E., et al. A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer 90 (2004) 985-990
18. Steffens M., Boerman O., de Mulder P., et al. Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res 5 (1999) 3268s-3274s
19. Divgi C., Bander N., Scott A., et al. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res 4 (1998) 2729-2739
20. Juweid M., and Cheson B. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 354 (2006) 496-507
21. NuDat database (cited Jun 5, 1996). http://nucleardata.nuclear.lu.se/database/nudat (accessed Feb 19, 2007)
22. Larson S., Pentlow K., Volkow N., et al. PET scanning of iodine-124-3F9 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma. J Nucl Med 33 (1992) 2020-2023
23. Larson SM, Finn R, Carrasquillo JA, et al. Antigen-specific composition and in vivo methods for detecting and localizing an antigenic site and for radiotherapy. US patent No. 5,185,142. Date: Feb 9, 1993.
24. Verel I., Visser G., Boerman O., et al. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET. Cancer Biother Radiopharm 18 (2003) 655-661
25. Welt S., Divgi C., Real F., et al. Quantitative analysis of antibody localization in human metastatic colon cancer: a phase I study of monoclonal antibody A33. J Clin Oncol 8 (1990) 1894-1906
26. Brouwers A., Dorr U., Lang O., et al. 131 I-cG250 monoclonal antibody immunoscintigraphy versus [18 F]FDG-PET imaging in patients with metastatic renal cell carcinoma: a comparative study. Nucl Med Commun 23 (2002) 229-236
27. Richstone L., Scherr D., Reuter V., et al. Multifocal renal cortical tumors: frequency, associated clinicopathological features, and impact on survival. J Urol 171 (2004) 615-620
28. Stevens L., Coresh J., Greene T., and Levey A. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 354 (2006) 2473-2483
29. Huang W., Levey A., Serio A., et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 7 (2006) 735-740